If the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...

In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...

India's Zydus Lifesciences is set to acquire an 85.6% stake in France's Amplitude Surgical for nearly $280 million to expand in the global ...

The company posted a consolidated net loss, from continuing operations, of 2.01 billion rupees ($24.14 million) for the three months ended ...

The Organisation of Pharmaceutical Producers of India (OPPI) has appointed Anil Matai as its director general. Matai has extensive experien...

The healthcare sector's impressive performance in the stock market highlights these companies' commitment to innovation, research, and deli...

Shares of Tata Chemicals and Canara Bank will be in focus today as the companies will go ex-dividend today. Tata Chemicals has also followe...

Zydus Lifesciences on Monday said it has received an approval from the Drug Controller General of India (DCGI) for Oxemia (Desidustat), a f...

The drug regulatory authority on Thursday approved Reliance Life Sciences, part of India's largest private sector enterprise-application, s...

Diabetic Macular Edema occurs when high blood sugar levels damage capillaries that leak fluid into the retina, resulting in swelling and bl...

Zydus is the fifth company to launch a copy of the antiviral in India after privately held Hetero Labs Ltd, Cipla, Mylan NV and Jubilant Li...

According to Xpheno, a staffing firm catering to the pharma sector, as many as 30,000 vacancies exist across the pharma space, in areas of ...

This week, Cipla, Jubilant Life Sciences, Hetero and Mylan signed non-exclusive licensing agreements for the antiviral drug which received ...

Bayer CropScience informed that the board appointed Pankaj Patel as an additional non-executive director of the company with effect from Ju...

Zydus Cadila has introduced a breast cancer drug in India that is a copy of Swiss giant Roche’s product Herceptin, which had global sales o...

Zydus Cadila is in early stages of talks to acquire Bangalore-based Strides Arcolab's Rs 70-crore domestic generic business.

Sharekhan has recommended ‘buy’ on Cadila Healthcare with a target price of Rs.372. At the current market price of Rs272, the stock is avai...